OSE Immunotherapeutics SA (EPA:OSE)

France flag France · Delayed Price · Currency is EUR
6.10
+0.04 (0.66%)
Sep 4, 2025, 1:41 PM CET
0.66%
Market Cap138.58M
Revenue (ttm)83.44M
Net Income (ttm)37.45M
Shares Out22.87M
EPS (ttm)1.46
PE Ratio4.15
Forward PE6.70
Dividendn/a
Ex-Dividend Daten/a
Volume16,657
Average Volume110,189
Open6.09
Previous Close6.06
Day's Range6.02 - 6.15
52-Week Range4.42 - 11.58
Beta0.45
RSI47.03
Earnings DateSep 26, 2025

About OSE Immunotherapeutics

OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 64
Stock Exchange Euronext Paris
Ticker Symbol OSE
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.